Biofil Chemicals & Pharmaceuticals Ltd.

As of June 30, 2026, Biofil Chemicals & Pharmaceuticals Ltd. carries a market capitalization of 563.56M, placing it among publicly traded companies globally. Its enterprise value stands at 563.56M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Biofil Chemicals & Pharmaceuticals Ltd. has 16.27M shares outstanding.

As of June 30, 2026, Biofil Chemicals & Pharmaceuticals Ltd. trades at a trailing price-to-earnings ratio of 115.29.

As of June 30, 2026, Biofil Chemicals & Pharmaceuticals Ltd. trades at an EV/EBITDA multiple of 71.84 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.64 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 110.50 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 563.56M versus a market cap of 563.56M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 13.73M in revenue per employee across its workforce of 25.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Biofil Chemicals & Pharmaceuticals Ltd. recorded 3.37M in income tax expense. That works out to an effective tax rate of 41.06, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 8.21M, leaving 4.84M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Biofil Chemicals & Pharmaceuticals Ltd.'s stock has declined approximately 25.57% over the past 52 weeks. The 50-day moving average sits at 31.62, while the 200-day moving average is 32.88.

Over the twelve months ended June 30, 2026, Biofil Chemicals & Pharmaceuticals Ltd. generated 343.13M in revenue and converted that into 4.84M in net income, yielding earnings per share of 0.30. EBITDA reached 7.85M, while operating income came in at 5.10M.

Over the twelve months ended June 30, 2026, Biofil Chemicals & Pharmaceuticals Ltd. posted a gross margin of 6.51, reflecting its pricing power and cost economics. The operating margin of 1.49 and net profit margin of 1.41 provide insight into operational efficiency.